284 related articles for article (PubMed ID: 9042254)
1. Concomitant point mutation of tumor suppressor gene p53 and oncogene c-N-ras in malignant neuroendocrine pancreatic tumor.
Hrasćan R; Pavelić K; Pavicić D; Krizanac S; Stajcer-Sittić V; Pecur L; Spaventi S; Klimpfinger M; Pavelić J
Anticancer Res; 1996; 16(6B):3761-6. PubMed ID: 9042254
[TBL] [Abstract][Full Text] [Related]
2. Ki-ras codon 12 point and P53 mutations: a molecular examination of the main tumor, liver, portal vein, peripheral arterial blood and para-aortic lymph node in pancreatic cancer.
Yamaguchi K; Chijiiwa K; Torato N; Kinoshita M; Tanaka M
Am J Gastroenterol; 2000 Aug; 95(8):1939-45. PubMed ID: 10950039
[TBL] [Abstract][Full Text] [Related]
3. Molecular genetics of malignant insulinoma.
Pavelic K; Hrascan R; Kapitanovic S; Vranes Z; Cabrijan T; Spaventi S; Korsic M; Krizanac S; Li YQ; Stambrook P; Gluckman JL; Pavelic ZP
Anticancer Res; 1996; 16(4A):1707-17. PubMed ID: 8712689
[TBL] [Abstract][Full Text] [Related]
4. p53, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas.
Weyrer K; Feichtinger H; Haun M; Weiss G; Ofner D; Weger AR; Umlauft F; Grünewald K
Lab Invest; 1996 Jan; 74(1):279-89. PubMed ID: 8569192
[TBL] [Abstract][Full Text] [Related]
5. Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women.
Gealy R; Zhang L; Siegfried JM; Luketich JD; Keohavong P
Cancer Epidemiol Biomarkers Prev; 1999 Apr; 8(4 Pt 1):297-302. PubMed ID: 10207632
[TBL] [Abstract][Full Text] [Related]
6. Multiple genetic alterations in malignant metastatic insulinomas.
Pavelić K; Hrasćan R; Kapitanović S; Karapandza N; Vranes Z; Belicza M; Kruslin B; Cabrijan T
J Pathol; 1995 Dec; 177(4):395-400. PubMed ID: 8568594
[TBL] [Abstract][Full Text] [Related]
7. Ki-ras mutations in codon 12 and p53 mutations (biomarkers) and cytology in bile in patients with hepatobiliary-pancreatic carcinoma.
Yamaguchi K; Nakano K; Nagai E; Chijiiwa K; Kinoshita M; Ohta M; Tanaka M
Hepatogastroenterology; 2005; 52(63):713-8. PubMed ID: 15966189
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of K-ras point mutation, telomerase activity, and p53 overexpression in pancreatic tumours.
Uemura K; Hiyama E; Murakami Y; Kanehiro T; Ohge H; Sueda T; Yokoyama T
Oncol Rep; 2003; 10(2):277-83. PubMed ID: 12579258
[TBL] [Abstract][Full Text] [Related]
9. Differences in K-ras and p53 gene mutations among pancreatic adenocarcinomas associated with regional environmental pollution.
Soliman AS; Lo AC; Banerjee M; El-Ghawalby N; Khaled HM; Bayoumi S; Seifeldin IA; Abdel-Aziz A; Abbruzzese JL; Greenson JK; Hamilton SR
Carcinogenesis; 2007 Aug; 28(8):1794-9. PubMed ID: 17575320
[TBL] [Abstract][Full Text] [Related]
10. p53 and K-RAS alterations in pancreatic epithelial cell lesions.
Kalthoff H; Schmiegel W; Roeder C; Kasche D; Schmidt A; Lauer G; Thiele HG; Honold G; Pantel K; Riethmüller G
Oncogene; 1993 Feb; 8(2):289-98. PubMed ID: 8426738
[TBL] [Abstract][Full Text] [Related]
11. Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma.
DiGiuseppe JA; Hruban RH; Offerhaus GJ; Clement MJ; van den Berg FM; Cameron JL; van Mansfeld AD
Am J Pathol; 1994 May; 144(5):889-95. PubMed ID: 8178941
[TBL] [Abstract][Full Text] [Related]
12. K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population-based study.
Slebos RJ; Hoppin JA; Tolbert PE; Holly EA; Brock JW; Zhang RH; Bracci PM; Foley J; Stockton P; McGregor LM; Flake GP; Taylor JA
Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1223-32. PubMed ID: 11097231
[TBL] [Abstract][Full Text] [Related]
13. Incidence of p53 and ras gene mutations in DMBA-induced rat leukemias.
Wei S; Kito K; Miyoshi A; Matsumoto S; Kauzi A; Aramoto T; Abe Y; Ueda N
J Exp Clin Cancer Res; 2002 Sep; 21(3):389-96. PubMed ID: 12385583
[TBL] [Abstract][Full Text] [Related]
14. Ki-ras codon 12 point mutation and p53 mutation in pancreatic diseases.
Yamaguchi K; Chijiiwa K; Noshiro H; Torata N; Kinoshita M; Tanaka M
Hepatogastroenterology; 1999; 46(28):2575-81. PubMed ID: 10522044
[TBL] [Abstract][Full Text] [Related]
15. p53 and K-ras in radon-associated lung adenocarcinoma.
McDonald JW; Taylor JA; Watson MA; Saccomanno G; Devereux TR
Cancer Epidemiol Biomarkers Prev; 1995; 4(7):791-3. PubMed ID: 8672998
[TBL] [Abstract][Full Text] [Related]
16. The potential diagnostic use of K-ras codon 12 and p53 alterations in brush cytology from the pancreatic head region.
Sturm PD; Hruban RH; Ramsoekh TB; Noorduyn LA; Tytgat GN; Gouma DJ; Offerhaus GJ
J Pathol; 1998 Nov; 186(3):247-53. PubMed ID: 10211112
[TBL] [Abstract][Full Text] [Related]
17. Genetic alterations in K-ras and p53 cancer genes in lung neoplasms from Swiss (CD-1) male mice exposed transplacentally to AZT.
Hong HH; Dunnick J; Herbert R; Devereux TR; Kim Y; Sills RC
Environ Mol Mutagen; 2007; 48(3-4):299-306. PubMed ID: 16395694
[TBL] [Abstract][Full Text] [Related]
18. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions.
Pellegata NS; Sessa F; Renault B; Bonato M; Leone BE; Solcia E; Ranzani GN
Cancer Res; 1994 Mar; 54(6):1556-60. PubMed ID: 8137263
[TBL] [Abstract][Full Text] [Related]
19. Expression and alteration of ras and p53 proteins in patients with lung carcinoma accompanied by idiopathic pulmonary fibrosis.
Takahashi T; Munakata M; Ohtsuka Y; Nisihara H; Nasuhara Y; Kamachi-Satoh A; Dosaka-Akita H; Homma Y; Kawakami Y
Cancer; 2002 Aug; 95(3):624-33. PubMed ID: 12209756
[TBL] [Abstract][Full Text] [Related]
20. c-k-ras and p53 mutations occur very early in adenocarcinoma of the lung.
Li ZH; Zheng J; Weiss LM; Shibata D
Am J Pathol; 1994 Feb; 144(2):303-9. PubMed ID: 8311114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
